Dr. Reddy's Laboratories Limited (DRREDDY)
🎯 Key Takeaways
- Dr. Reddy's Laboratories is in a mature phase of growth with stable profitability and low leverage, maintaining strong returns on capital despite flat revenue trends over the past year.
- Revenue declined 0.8% QoQ to ₹8,753 in Q3FY26.
- ⚠️ Persistent decline in revenue and margins over multiple quarters suggests potential competitive or demand-side pressures in key therapeutic segments.
📖 The Story
Dr. Reddy's Laboratories is in a mature phase of growth with stable profitability and low leverage, maintaining strong returns on capital despite flat revenue trends over the past year. Management continues to focus on operational efficiency and incremental expansion through employee stock allocations, signaling confidence in long-term fundamentals. The company operates with a conservative capital structure and high ROCE, positioning it as a resilient player in the global generics and pharmaceuticals space.
📰 What's Happening
In the last three quarters, Dr. Reddy's has scheduled the announcement of Q1FY27 results for July 22, 2026, following a board meeting on the same date to review unaudited standalone and consolidated financials for the quarter ending June 30, 2026. The company has also made two separate equity allotments under its employee stock option schemes in June 2026 — first allotting 12,100 shares on June 5 and later 6,730 shares on June 19 — increasing total issued share capital to approximately Rs. 83.47 crore. These moves reflect routine equity compensation practices but contribute marginally to dilution. No new strategic initiatives or M&A activity has been disclosed recently, and the company has not provided forward guidance in any of the filings.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7,114 | 7,696 | 8,038 | 8,381 | 8,528 | 8,572 | 8,828 | 8,753 |
| Operating Profit | 2,029 | 2,317 | 2,384 | 2,423 | 2,520 | 2,464 | 2,334 | 2,156 |
| OPM % | 25.7% | 27.7% | 25.8% | 27.1% | 23.4% | 25.4% | 22.8% | 21.6% |
| Net Profit | 1,310 | 1,392 | 1,342 | 1,404 | 1,587 | 1,410 | 1,337 | 1,190 |
| EPS | ₹78.66 | ₹83.61 | ₹15.08 | ₹16.97 | ₹19.12 | ₹17.04 | ₹16.18 | ₹14.53 |
Dr. Reddy's has experienced a sustained decline in revenue and profitability over the past four quarters, with total income falling from ₹8,753 crore in Q3FY26 to ₹7,114 crore in Q4FY24, and net profit decreasing from ₹1,587 crore to ₹1,190 crore over the same period. Operating margins have also compressed from a peak of 27.1% in Q3FY25 to 21.6% in Q3FY26, indicating margin pressure despite cost control efforts. Earnings per share has declined significantly, dropping from ₹19.12 in Q4FY25 to ₹14.53 in Q3FY26, reflecting both lower profits and share consolidation effects. This downward trend in financial performance appears to be a key factor behind the upcoming earnings call, though management has not yet attributed it to specific external or internal causes in the disclosed filings.
🔮 Management Outlook & What's Next
Management has not provided any forward-looking guidance or commentary on future performance in the reviewed filings, including those related to the upcoming Q1FY27 results announcement. The company has only confirmed the timing of its earnings call but has not disclosed expectations for revenue recovery, margin improvement, or capital allocation strategy beyond routine operational updates. As such, there is no explicit outlook on growth drivers, market conditions, or therapeutic segment performance available from the latest disclosures.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | 2023-2024 | 2023-2024 | 2024-2025 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|
| Equity Capital | 83 | 83 | 83 | 83 | 84 |
| Reserves | 25,413 | 28,171 | 30,666 | 33,466 | 35,931 |
| Borrowings | 1,323 | 1,652 | 4,382 | 4,185 | 4,496 |
| Total Liabilities | 9,313 | 10,609 | 15,585 | 15,499 | 18,000 |
| Fixed Assets | 5,850 | 6,249 | 6,726 | 7,298 | 9,119 |
| Investments | 4,051 | 4,511 | 3,185 | 3,570 | 4,183 |
| Total Assets | 34,809 | 38,864 | 46,728 | 49,427 | 54,373 |
The balance sheet shows a stable and conservative capital structure, with equity increasing slightly from ₹83 crore to ₹84 crore and reserves growing from ₹33,466 crore to ₹35,931 crore over the latest two fiscal years, indicating retained earnings accumulation. Borrowings have risen modestly from ₹4,185 crore to ₹4,496 crore, suggesting slight deleveraging is not underway, but the debt-to-equity ratio remains low at 0.12, reflecting strong solvency. Total assets have expanded from ₹46,728 crore to ₹54,373 crore, driven by asset growth outpacing liability increases, which supports a stable operational foundation despite flat top-line trends.
💰 Cash Flow Statement (₹ Cr)
| Item | 2020-2021 |
|---|---|
| Operating | +3,570 |
| Investing | -2,266 |
| Financing | -30 |
| Net Cash Flow | — |
⚖️ Peer Comparison — Pharmaceuticals & Biotechnology
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 4.51 L Cr | 41.3 | 20.3% | 15.1% | 0.03 |
| Divi's Laboratories Limited | 1.79 L Cr | 72.4 | 22.1% | 16.6% | 0.00 |
| Torrent Pharmaceuticals Limited | 1.49 L Cr | 80.1 | — | — | — |
| Cipla Limited | 1.16 L Cr | 25.4 | 19.4% | 14.6% | 0.00 |
| Dr. Reddy's Laboratories Limited | 1.12 L Cr | 20.0 | 19.7% | 16.6% | 0.12 |
| Lupin Limited | 1.04 L Cr | 36.2 | — | — | — |
| Mankind Pharma Limited | 1.03 L Cr | 49.2 | — | — | — |
| Zydus Lifesciences Limited | 1.02 L Cr | 22.5 | — | — | — |
| Aurobindo Pharma Limited | 87,806 | 25.3 | — | — | — |
| Laurus Labs Limited | 71,455 | 356.8 | — | — | — |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Persistent decline in revenue and margins over multiple quarters suggests potential competitive or demand-side pressures in key therapeutic segments. 2. No forward guidance or strategic commentary from management leaves uncertainty about the sustainability of profitability. 3. Low but rising borrowings combined with flat growth may limit flexibility if macroeconomic or regulatory headwinds intensify. 4. Minimal dilution from employee stock allocations is offset by the broader trend of declining financial performance, which could pressure future investment in R&D or global expansion.
📋 Recent Filings
-
🔴 Financial Results 13 July 2026Dr. Reddy's Laboratories announced it will release Q1FY27 results on Wednesday, July 22, 2026 after the board meeting, followed by an earnings call at...
-
share transfer 3 July 2026Dr. Reddy's Laboratories disclosed a SEBI-mandated confirmation certificate from its share transfer agent, Bigshare Services Private Limited, covering...
-
Announcement 25 June 2026Dr. Reddy's Laboratories announced that the USFDA completed a Pre-License Inspection at its Bachupally biologics facility in Hyderabad from June 16 to...
-
Financial Results 22 June 2026Dr. Reddy's Laboratories announced that its board will meet on July 22, 2026, to review unaudited standalone and consolidated financial results for th...
-
🔴 Corporate Action 19 June 2026Dr. Reddy's Laboratories allotted 6,730 fully paid equity shares of Re.1 each to eligible employees on June 19, 2026, through exercise of stock option...
-
Announcement 13 June 2026Dr. Reddy's Laboratories announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States on Ju...
-
🔴 Announcement 12 June 2026No summary available
-
Announcement 10 June 2026Dr. Reddy's Laboratories announced its participation in an investor conference organized by Investec London on June 16-17, 2026, conducted as an in-pe...
-
🔴 Corporate Action 5 June 2026Dr. Reddy's Laboratories allotted 12,100 fully paid equity shares of Re.1 each to eligible employees on June 5, 2026, through exercise of stock option...
-
Announcement 3 June 2026Dr. Reddy's Laboratories announced its schedule for upcoming investor meetings, including an in-person group session with ICICI Securities in Mumbai o...
🧠 Analyst's Read
Dr. Reddy's is navigating a challenging phase marked by declining financial momentum and limited strategic clarity, despite a strong balance sheet and consistent returns on capital. Investors should monitor the upcoming Q1FY27 results and earnings call for early signals of stabilization or further deterioration, particularly around margin trends and segment performance. The absence of guidance or new initiatives warrants caution, though the company's fundamentals remain intact.
Based on filing content and financial data. Not a recommendation.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-14.
📡 Get AI alerts when DRREDDY files new disclosures
Track DRREDDY filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track DRREDDY — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research